Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Virulizin results published; FDA grants orphan drug status to GTI-2040
April 22nd, 2003
Scientists at Lorus Therapeutics, Inc., have published the results of experimental studies in mouse models bearing human tumors treated with Virulizin, the company's lead anticancer immunotherapeutic drug. Virulizin showed significant antitumor activity as a monotherapy and enhanced antitumor effects when used in combination with standard chemotherapy agents against a panel of human pancreatic tumors and melanoma. The results appear in an article titled "Anti-tumor activity of Virulizin, a novel biological response modifier (BRM), in a panel of human pancreatic cancer and melanoma xenografts," in the March issue of Cancer Chemotherapy and...
Source: Cancer Weekly (2003-04-22)
|
